text:
Artist: Stewart Jones
Title: When Pigs Fly Pendant
Medium: Sterling Silver w/ 18k gold wings
Size: 1″ snout to tail
Price (USA Dollars): $370
Please call or email us for shipping costs.
TO ORDER this item from Stewart Jones Designs:
please call
or email
International sales are
"Port of Entry".
Please have the following information ready when ordering:
Artist's Name
Payment Information
We accept Checks or Visa, Mastercard, American Express & Discover cards.
LAY-A-WAY is available. We will gladly work with you on a plan that meets your needs.
REFUND POLICY: If the item you order does not meet your expectations for any reason, you may return it to us undamaged and unaltered in any way within 14 days for a full refund EXCLUDING all shipping charges.
Thank you


text:
Contact: Katie Blocher email@example.com 212-838-2560
Society of Illustrators Announces Plans For Inaugural MoCCA Arts Festival
NEW YORK, NY (December 14, 2012) - The Society of Illustrators is proud to increase the visibility of comics as a major component of its storied institutional mission by hosting the MoCCA Arts Festival on the weekend of April 6-7, 2013 at the 69th Regiment Armory in Manhattan. Beginning in 2013, the MoCCA Arts Festival will be one of the Society's signature public programs, with the mission of honoring the artists who are advancing the landscape of comics and illustration via a world-class festival emphasizing their achievements.
Anelle Miller, Executive Director of the Society of Illustrators, says, "It is a great privilege to welcome the incredibly dynamic creative community that exhibits at the MoCCA Arts Festival to the Society's rich heritage. For more than a century, our mission has been to promote the art of illustration, and to appreciate its history and evolving nature through exhibitions, lectures and education. We are elated to host the MoCCA Arts Festival as a key component of that mission, and to honor its artists with the high caliber of exhibitions and recognition that are the Society's trademark."
In addition to continuing the Festival's tradition of hosting an exhibit hall spotlighting comics' leading edge creators, the MoCCA Arts Festival will now include a variety of new programs directly benefiting the artist and audience communities attending the shows, including:
* Juried awards recognizing the best work at the Festival with medal winners being honored with an exhibit at the Society's headquarters, and finalists' work archived in Columbia University's Rare Book and Manuscript Library;
* A lavishly produced, large format souvenir journal that showcases the work of exhibiting artists;
* Discount entries for exhibiting artists in the Society's Annual competition;
* Curated programming emphasizing the artistic achievements of the Festival's creative community;
* An exhibition gallery of original comic and cartoon art curated by the Society's professional staff;
* An onsite café featuring a full bar and menu as well as a lounge for networking.
The 2013 MoCCA Arts Festival is hosted by the Society of Illustrators, under the guidance of a Steering Committee that includes: Anelle Miller, Kate Feirtag, and Katie Blocher from the Society, as well as Leon Avelino (Secret Acres), Charles Brownstein (Comic Book Legal Defense Fund), Karen Green (Columbia University), William Hatzichristos (CollectorZoo), Paul Levitz (Writer/ Educator), Barry Matthews (Secret Acres), and Tucker Stone (Bergen Street Comics).
In the weeks to come, the Society will release more details about the 2013 Festival, including naming guests of honor, featured guests, the Festival jury, and much more.
About the Museum of American Illustration at the Society of Illustrators:
The Society of Illustrators, founded in 1901, is the oldest nonprofit organization solely dedicated to the art and appreciation of illustration in America. Prominent Society members have been
Maxfield Parrish, N.C. Wyeth and Norman Rockwell, among others. The Museum of American Illustration was established by the Society in 1981 and is located in the Society's vintage 1875 carriage house building in mid-town Manhattan. It is open to the public free of charge on Tuesday, 10 am-8 pm; Wednesday-Friday, 10 am-5 pm; and Saturday, 12-4 pm. To learn more about the Museum and the Society, visit www.societyillustrators.org or contact Executive Director Anelle Miller at 212-838-2560 or email@example.com.
About the Museum of Comic and Cartoon Art
The museum's purpose has been the collection, preservation, study, education, and display of comic and cartoon art. Every genre of the art is represented: animation, anime, cartoons, comic books, comic strips, gag cartoons, humorous illustration, illustration, political illustration, editorial cartoons, caricature, graphic novels, sports cartoons, and computer-generated art. It is the mission of the museum to promote the understanding and appreciation of comic and cartoon art as well as to detail and discuss the artistic, cultural, and historical impact of what is the world's most popular art form.

subset: commoncrawl


text:
The summer of 1956 marked the first full season of racing at Road America, and it included the Chicago Region June Sprints. This weekend, new names were added to the WeatherTech Chicago Region June Sprints history book with the 62nd running of the event, which is part of the 2017 Hoosier Racing Tire SCCA® Super Tour. Who won and how did they accomplish victory? Find out in the videos below.
The premier U.S. amateur road racing series, Hoosier Racing Tire SCCA Super Tour is comprised of an exciting, 11-weekend schedule that brings together top SCCA Club competitors from throughout the country. Visiting some of the greatest tracks in North America, each weekend consists of two races for each of 28 car classes. From GT cars to production vehicles, formula cars to prototypes, the Hoosier Super Tour packs a ton of great action into each and every weekend.


text:
Slovak Airlines
Slovak Airlines was an airline company offering flights from and to several cities in Slovakia. Cheap flights to Slovakia from UK, for example. The airlines also flew scheduled services from Bratislava to Brussels, Belgium (7 weekly, codeshare with Austrian, Fokker 100) and Moscow Sheremetyevo (4 weekly, codeshare Aeroflot, Fokker 100).
After the break-up of the former Czechoslovakia, the Slovak Republic found itself in a specific situation in the area of air transport, in that no transport company remained and even in the past there had never been an effective network of airlines directly connecting Slovakia with the rest of the world. Not a single aircraft or foreign embassy remained in Slovakia.
To resolve this unsatisfactory situation the need had long been felt to build a transport company ensuring the connection of Slovakia with foreign countries and to resolve the entire conception of air transport, in particular in connection with tourism and the creation of an infrastructure (technical furnishings, catering, handling etc.)
In 1995 the mission of the International Civil Aviation Organisation (ICAO) on a visit to Slovakia proposed the creation of a national air transport company as one possibility of the development of civil aviation. Even before a number of aviation companies had contended for this status, but their efforts had been unsuccessful. After almost one year of intensive discussions experts agreed on the idea that it would be possible to create a strong, high quality airline company in Slovak conditions only in the form of a national airline company. The result of this endeavour was the designation of the company Slovenské aerolínie a.s. [Slovak Airlines, joint stock company] as the national air transport company.
The business plan of Slovak Airlines began with the construction of a basic network of lines over a period of 5 years.
Within the framework of the Phare programme "Air Operation Safety Improvement", Slovak Airlines was selected as one of three operators within the states of Eastern Europe as a sample transport company and consultant in the creation of a programme of improving safety of air transport in the Phare countries.
The general secretary of the United Aviation Authorities of Europe, Mr. Kouplin highly evaluated the achieved technical standard and capability of the TU-154M aircrafts and invited Slovak Airline to participate in the creation of the prescription basis for the states of the European Commission for civil aviation (ECAC). He evaluated the standard of the Slovak air company according to Western European aviation prescriptions.
In 2006 Slovak Airlines j. s. c. obtained financial support from Austrian Airlines, in the total amount of 200 million SKK (about 7 mil. euro). The intention of AUA was to contribute to the realization of Slovak Airlines business plan, with financial support, business experience and know-how.
"The Company has been struggling to raisefunds for a long period of time and therefore needs external sources. We started looking for a strategic partner a year ago and we addressed several companies, only Austrian Airlines showed interest," explains Slovak Airlines spokesman.
This process was approved by Slovak airlines majority owner, the Ministry of transport, post and telecommunications.
Business activities in the last months were severly affected by not delivering of a small low cost airplane Fokker 100. Slovak Airlines is a small air carrier and delayed delivery complicated the fulfilling of business plan. Fokker operated less popular routes where the operation of larger aircraft Boeing is not cost effective, it is uselessly and expensive.
Slovak airlines has been closely co-operating with Austrian Airlines from May 2004. Together they operated regular lines from Bratislava to London, Brussels and Paris.
Slovakian Airlines
Slovakian Airlines was an airline carier which started operating on 20th of September 2011 when the first airplane of Slovakian Airlines Boeing 737-500 landed at the airport of Milan Rastislav Štefánik in Bratislava. It arrived from Norwich, UK, where it has received new colors of Slovakian Airlines. The aircraft, which previously operated Czech Airlines, is leased from the Armenian airline Armavia.
The capacity of the first aircraft has 84 seats in economy class and 24 seats in business class. After obtaining the necessary licenses from December 2011, Slovakian Airlines plans to provide scheduled air services.
Slovakian Airlines was a private airline owned by the Slovak entrepreneur Arnold Medzihradský and Mikhail Bagdasar from Russia.


text:
At Luther, we try to prepare our students to serve in the world. One of the ways in which we do this is through helping students to become servant-leaders. Servant-leaders are persons who serve others and help them to reach their fullest potential. The concept of servant-leadership asserts that no act of service is without elements of leadership, and certainly no act of true leadership is without elements of service.
There are many ways for students to act as a servant-leader while here at Luther, including:


text:
Department of Health and Human Services
Participating Organizations
National Institutes of Health (NIH) (http://www.nih.gov)
Components of Participating Organizations
National Institute of Biomedical Imaging and Bioengineering (NIBIB) (http://www.nibib.nih.gov)
National Heart, Lung, and Blood Institute (NHLBI) (http://www.nhlbi.nih.gov)
Title: Development of Multifunctional
Drug and Gene Delivery Systems (R01)
Announcement Type
Update: The following updates relating to this announcement have been issued:
Program Announcement (PA)
Number: PAR-10-048
NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.
This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants (hereafter called Grants.gov/Apply).
A registration process is necessary before submission and applicants are highly encouraged to start the process at least four (4) weeks prior to the grant submission date. See Section IV.
Catalog of Federal Domestic Assistance Number(s)
93.286, 93.394, 93.396
Key Dates
Release/Posted Date: December 7, 2009
Opening Date: January 5, 2010 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): 30 days before Application Due Dates
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Due Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm
AIDS Application Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS.
Peer Review Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Council Review Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Earliest Anticipated Start Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Additional Information To Be Available Date (URL Activation Date): Not Applicable
Expiration Date: January 8, 2013
Due Dates for E.O. 12372
Not Applicable
Overview Content
Executive Summary
Table of Contents
Part I Overview
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2. Cost Sharing or Matching
3. Other-Special Eligibility Criteria
Section IV. Application and Submission Information
1. Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Submission, Review, and Anticipated Start Dates
1. Letter of Intent
B. Submitting an Application Electronically to the NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Resource Sharing Plan(s)
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
3. Reporting
Section VII. Agency Contacts
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/Grants Management Contact(s)
Section VIII. Other Information - Required Federal Citations
Part II - Full Text of Announcement
Section I. Funding Opportunity Description
Research Objectives
Novel drug and gene therapies continue to be developed to treat various diseases. However, only a limited number advance to the clinical stage due to side effects, toxicity, and/or the lack of efficacy. Research efforts that focus on the engineering of targeted delivery systems to improve in vivo delivery are needed. Such systems should address at least three major challenges in the field of drug and gene delivery: (1) targeting of therapies to tissues, cells, and intracellular compartments; (2) monitoring exactly where the therapies localize after administration; and (3) determining if the agents delivered are doing what they were intended to do. Various imaging technologies, such as PET, SPECT, MRI, optical and ultrasound are well suited to study the in vivo characteristics and function of targeted delivery systems. Recent studies have shown the ability to quantify the location and magnitude of delivery and/or gene expression in real-time using PET, SPECT, and MRI in conjunction with molecular probes or signatures. Advances in multimodal imaging systems, such as MRI and PET, CT and SPECT, CT and PET, or MRI and optical imaging systems are also suitable for the real-time assessment of not just targeted therapy with enhanced efficacy, but also the identification of quantitative in vivo relationships between the carrier and cellular events, which in turn, will lead to new engineering design principles.
Research Objectives
The objective of this FOA is to support research on the development of novel, multifunctional systems that are capable of targeted delivery of drugs, proteins, genes, and other nucleic acids to specific cells, or compartments within cells, in vivo, and that possess imaging or sensing capabilities to track delivery and determine therapeutic efficacy. To achieve the goal, research applications submitted to this FOA should include the development, modification, or integration of advanced imaging/sensing technologies together with delivery technologies that allow for qualitative and quantitative analysis and interpretation of in vivo behavior. It is anticipated that new methods, concepts, and technical approaches will be needed to assess the in vivo performance of these multifunctional delivery systems in real-time which may include non-invasive imaging techniques coupled with biomarkers and sensors for the quantitative assessment of the location, magnitude, and time variation of drug release, gene expression and transfection, or other appropriate therapeutic measures. In addition to testing efficacy, studies that focus on particle trafficking and in vivo transport are also desirable to assess function and to elucidate the mechanisms of cellular targeting, cellular entry, endosomal processing, nuclear transport, or intracellular interactions that regulate attachment and therapeutic release. These pharmacokinetic, pharmacodynamic, and mechanistic studies are mostly limited to in vivo testing but may include some ex vivo experiments if necessary and deemed appropriate.
Efforts to adapt or develop statistical and computational models to guide the engineering and prediction of behavior of the new delivery systems are encouraged but not required. For example, models can be used to evaluate the overall design features, identify key parameters or gaps to be addressed in the research plan, or enable researchers to test new hypotheses. Moreover, the key parameters and structure-function relationships that result from the above physicochemical characterization and intracellular fate studies, can in turn, be used to develop new models and design principles to develop efficient targeted delivery systems.
Applications submitted to this FOA should include investigators from both the drug/gene delivery and imaging fields. Applicants are strongly encouraged to use the Multi-PD/PI model to meet the required imaging and drug/gene delivery expertise. Applications from a single Principal Investigator will be considered if he/she has significant expertise in both imaging and drug/gene delivery technology.
Research Examples of Multifunctional Drug and Gene Delivery Systems: The engineering of novel multifunctional therapeutic delivery systems must combine drug or gene targeting delivery systems with imaging and/or sensing capabilities to meet the objectives of this FOA. Delivery systems should have at least 3 components: (1) a targeting moiety or molecular signatures that can target delivery to specific sites, (2) the appropriate imaging agent/probe/tags for visualization or monitoring of the systems, and (3) a therapeutic agent to effectively treat a particular disease or disorder.
The following are examples of multifunctional delivery systems that contain targeting, imaging, and drug/gene moieties. This list is not intended to be exclusive or to limit creativity and innovation in the overall design of a delivery system. Targeted systems that can be activated by internal processes such as pH, enzyme cleavage or external stimuli such as near IR light, ultrasound, or magnetic field for therapeutic delivery and imaging are also suitable.
Specific Interests
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is interested in supporting the development of multifunctional drug and gene delivery systems as described above and does not limit projects to a specific type of disease or disorder. The National Heart, Lung, and Blood Institute (NHLBI) is interested in projects developing multifunctional drug and gene delivery systems as described above to heart, lung, and blood diseases. Applications focused on lung or blood cancers are outside the scope of NHLBI's interests.
See Section VIII, Other Information - Required Federal
Citations, for policies related to this
Section II. Award Information
This FOA will use the R01 grant award mechanism. The Project Director/Principal Investigator (PD/PI) will be solely responsible for planning, directing, and executing the proposed project.
This FOA uses "Just-in-Time" information concepts (see SF424 (R&R) Application Guide). It also uses the modular as well as the non-modular budget formats (see https://grants.nih.gov/grants/funding/modular/modular.htm). Specifically, a U.S. organization submitting an application with direct costs in each year of $250,000 or less (excluding consortium Facilities and Administrative [F&A] costs) should use the PHS398 Modular Budget component.
U.S. applicants requesting more than $250,000 in annual direct costs and all foreign applicants must complete and submit budget requests using the Research & Related Budget component.
Funds Available
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the IC(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds.
Facilities and Administrative (F&A) costs requested by consortium participants are not included in the direct cost limitation, see NOT-OD-05-004.
NIH grants policies as described in the http://era.nih.gov/ElectronicReceipt/preparing.htm for instructions).
The decision of whether to apply for a grant with a single PD/PI or multiple PDs/PIs grant is the responsibility of the investigators and applicant organizations and should be determined by the scientific goals of the project. Applications for grants with multiple PDs/PIs will require additional information, as outlined in the instructions below. When considering the multiple PD/PI option, please be aware that the structure and governance of the PD/PI leadership team as well as the knowledge, skills and experience of the individual PDs/PIs will be factored into the assessment of the overall scientific merit of the application. Multiple PDs/PIs on a project share the authority and responsibility for leading and directing the project, intellectually and logistically. Each PD/PI is responsible and accountable to the grantee organization, or, as appropriate, to a collaborating organization, for the proper conduct of the project or program, including the submission of required reports. For further information on multiple PDs/PIs, please see https://grants.nih.gov/grants/multi_pi.
2. Cost
Sharing or Matching
This program does not require cost sharing as defined in the current NIH Grants Policy Statement.
3. Other-Special Eligibility Criteria
Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct.
Resubmissions. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Beginning with applications intended for the January 25, 2009 official submission due date, all original new applications (i.e., never submitted) and renewal applications are permitted only a single amendment (A1). See new NIH policy on resubmission (amended) applications (NOT-OD-09-003, NOT-OD-09-016). Original new and competing renewal applications that were submitted prior to January 25, 2009 are permitted two amendments (A1 and A2). For these "grandfathered" applications, NIH expects that any A2 will be submitted no later than January 7, 2011, and NIH will not accept A2 applications after that date.
Renewals. Applicants may submit a renewal application.
Section IV. Application and Submission Information
download a SF424 (R&R) Application Package and SF424 (R&R) Application
Guide for completing the SF424 (R&R) forms for this FOA, use the "Apply for
Grant Electronically" button in this FOA or link to http://www.grants.gov/Apply/ and follow
the directions provided on that Web site.
Appropriate registrations with Grants.gov and eRA Commons must be completed on or before the due date in order to successfully submit an application. Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered with both Grants.gov and the Commons. All registrations must be complete by the submission deadline for the application to be considered "on-time" (see 3.C.1 for more information about on-time submission).
A one-time registration is required for institutions/organizations at both:
PDs/PIs should work with their institutions/organizations to make sure they are registered in the NIH eRA Commons.
Several additional separate actions are required before an applicant can submit an electronic application, as follows:
1) Organizational/Institutional Registration in Grants.gov/Get Registered
2) Organizational/Institutional Registration in the eRA Commons
3) Project Director/Principal Investigator (PD/PI) Registration in the NIH eRA Commons: Refer to the NIH eRA Commons System (COM) Users Guide.
Both the PD(s)/PI(s) and AOR/SO need separate accounts in the NIH eRA Commons since both are authorized to view the application image.
Note: The registration process is not sequential. Applicants should begin the registration processes for both Grants.gov and eRA Commons as soon as their organization has obtained a DUNS number. Only one DUNS number is required and the same DUNS number must be referenced when completing Grants.gov registration, eRA Commons registration and the SF424 (R&R) forms.
1. Request Application Information
Applicants must download the SF424 (R&R) application forms and the SF424 (R&R) Application Guide for this FOA through Grants.gov/Apply.
Only the forms package directly attached to a specific FOA can be used. You
will not be able to use any other SF424 (R&R) forms (e.g., sample forms,
forms from another FOA), although some of the "Attachment" files may
be useable for more than one FOA.
For further assistance, contact GrantsInfo -- Telephone 301-710-0267, Email: firstname.lastname@example.com.
Telecommunications for the hearing impaired: TTY: (301) 451-5936
2. Content and Form of Application Submission
Prepare all applications using the SF424 (R&R) application forms and in accordance with the SF424 (R&R) Application Guide for this FOA through Grants.gov/Apply.
The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to NIH. Some fields within the SF424 (R&R) application components, although not marked as mandatory, are required by NIH (e.g., the "Credential" log-in field of the "Research & Related Senior/Key Person Profile" component must contain the PD/PI's assigned eRA Commons User ID). Agency-specific instructions for such fields are clearly identified in the Application Guide. For additional information, see "Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications."
The SF424 (R&R) application has several components. Some components are required, others are optional. The forms package associated with this FOA in Grants.gov/APPLY includes all applicable components, required and optional. A completed application in response to this FOA includes the data in the following components:
Required Components:
SF424 (R&R) (Cover component)
Research & Related Project/Performance Site Locations
Research & Related Other Project Information
Research & Related Senior/Key Person
PHS398 Cover Page Supplement
PHS398 Research Plan
PHS398 Checklist
PHS398 Modular Budget or Research & Related Budget, as appropriate (See Section IV.6., "Special Instructions," regarding appropriate required budget component.)
Optional Components:
PHS398 Cover Letter File
Research & Related Subaward Budget Attachment(s) Form
Organizations (Non-domestic [non-U.S.] Entities)
NIH policies concerning grants to foreign (non-U.S.) organizations can be found in the NIH Grants Policy Statement at: https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm#_Toc54600260.
Applications from Foreign organizations must:
Proposed research should provide special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions in other countries that are not readily available in the United States (U.S.) or that augment existing U.S. resources.
Applications with Multiple PDs/PIs
When multiple PDs/PIs are proposed, NIH requires one PD/PI to be designated as the "Contact" PI, who will be responsible for all communication between the PDs/PIs and the NIH, for assembling the application materials outlined below, and for coordinating progress reports for the project. The contact PD/PI must meet all eligibility requirements for PD/PI status in the same way as other PDs/PIs, but has no other special roles or responsibilities within the project team beyond those mentioned above.
Information for the Contact PD/PI should be entered in item 15 of the SF424 (R&R) Cover component. All other PDs/PIs should be listed in the Research & Related Senior/Key Person component and assigned the project role of "PD/PI." Please remember that all PDs/PIs must be registered in the eRA Commons prior to application submission. The Commons ID of each PD/PI must be included in the "Credential" field of the Research & Related Senior/Key Person component. Failure to include this data field will cause the application to be rejected.
All projects proposing Multiple PDs/PIs will be required to include a new section describing the leadership plan approach for the proposed project.
Multiple PD/PI Leadership Plan: For applications designating multiple PDs/PIs, a new section of the Research Plan, entitled "Multiple PD/PI Leadership Plan" must be included. A rationale for choosing a multiple PD/PI approach should be described. The governance and organizational structure of the leadership team and the research project should be described, and should include communication plans, process for making decisions on scientific direction, and procedures for resolving conflicts. The roles and administrative, technical, and scientific responsibilities for the project or program should be delineated for the PDs/PIs and other collaborators.
If budget allocation is planned, the distribution of resources to specific components of the project or the individual PDs/PIs should be delineated in the Leadership Plan. In the event of an award, the requested allocations may be reflected in a footnote on the Notice of Award (NoA).
Applications Involving a Single Institution
When all PDs/PIs are within a single institution, follow the instructions contained in the SF424 (R&R) Application Guide.
Applications Involving Multiple Institutions
When multiple institutions are involved, one institution must be designated as the prime institution and funding for the other institution(s) must be requested via a subcontract to be administered by the prime institution. When submitting a detailed budget, the prime institution should submit its budget using the Research & Related Budget component. All other institutions should have their individual budgets attached separately to the Research & Related Subaward Budget Attachment(s) Form. See Section 4.8 of the SF424 (R&R) Application Guide for further instruction regarding the use of the subaward budget form.
When submitting a modular budget, the prime institution completes the PHS398 Modular Budget component only. Information concerning the consortium/subcontract budget is provided in the budget justification. Separate budgets for each consortium/subcontract grantee are not required when using the Modular budget format. See Section 5.4 of the Application Guide for further instruction regarding the use of the PHS398 Modular Budget component.
3. Submission Dates and Times
See Section IV.3.A. for details.
3.A. Submission, Review, and
Anticipated Start Dates
Opening Date: Jaunary 5, 2010 (Earliest date an application may be submitted to Grants.gov).
Letters of Intent Receipt Date(s): 30 days before Application Due Dates
Application Due Date(s): Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm
AIDS Application Due Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS
Peer Review Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Council Review Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Earliest Anticipated Start Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent that includes the following information:
a letter of intent is not required, is not binding, and does not enter into the
review of a subsequent application, the information that it contains allows IC
staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed in Section IV.3.A.
The letter of intent should be sent to:
Steven Zullo, Ph.D.
Gene and Drug Delivery, Nanotechnology Program Director
NIBIB, Division of Discovery Science and Technology
Democracy II-227
GIBB (Govt Issued Blackberry): 240-271-7097
Fax: 301-480-1614
3.B. Submitting an Application Electronically to the NIH
To submit an application in response to this FOA, applicants should access this FOA via http://www.grants.gov/web/grants/applicants/apply-for-grants.html and follow Steps 1-4. Note: Applications must only be submitted electronically. PAPER APPLICATIONS WILL NOT BE ACCEPTED.
Application Processing
3.C.1 Submitting On-Time
Applications may be submitted on or after the opening date and must be successfully received by Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization) on the application due date(s). (See Section IV.3.A. for all dates.) If an application is not submitted by the due date(s) and time, the application may be delayed in the review process or not reviewed. All applications must meet the following criteria to be considered "on-time":
Please visit http://era.nih.gov/electronicReceipt/app_help.htm for detailed information on what to do if Grants.gov or eRA system issues threaten your ability to submit on time.
Submission to Grants.gov is not the last step – applicants must follow their application through to the eRA Commons to check for errors and warnings and view their assembled application!
3.C.2 Two Day Window to Correct eRA Identified Errors/Warnings
IMPORTANT NOTE! NIH has eliminated the error correction window for due dates of January 25, 2011 and beyond. As of January 25, all corrections must be complete by the due date for an application to be considered on-time. See NOT-OD-10-123.
Once an application package has been successfully submitted through Grants.gov, NIH provides applicants a two day error correction window to correct any eRA identified errors or warnings before a final assembled application is created in the eRA Commons. The standard error correction window is two (2) business days, beginning the day after the submission deadline and excluding weekends and standard federal holidays. All errors must be corrected to successfully complete the submission process. Warnings will not prevent the application from completing the submission process.
Please note that the following caveats apply:
3.C.3 Viewing an Application in the eRA Commons
Once any eRA identified errors have been addressed and the assembled application has been created in the eRA Commons, the PD/PI and the Authorized Organization Representative/Signing Official (AOR/SO) have two weekdays (Monday – Friday, excluding Federal holidays) to view the assembled application before it automatically moves forward to NIH for further processing.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Incomplete applications will not be reviewed.
There will be an acknowledgement of receipt of applications from Grants.gov and the Commons. The submitting AOR/SO receives the Grants.gov acknowledgments. The AOR/SO and the PI receive Commons acknowledgments. Information related to the assignment of an application to a Scientific Review Group is also in the Commons.
Note: Since email can be unreliable, it is the responsibility of the applicant to check periodically on their application status in the Commons.
The NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial merit review unless the applicant withdraws the pending application. The NIH will not accept any application that is essentially the same as one already reviewed. However, the NIH will accept a resubmission application, but such application must include an Introduction addressing the critique from the previous review.
4. Intergovernmental Review
This initiative is not subject to intergovernmental review.
5. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
costs are allowable. A grantee may, at its own risk and without NIH prior
approval, incur obligations and expenditures to cover costs up to 90 days
before the beginning date of the initial budget period of a new or renewal
award if such costs: 1) are necessary to conduct the project, and 2) would be
allowable under the grant, if awarded, without NIH prior approval. If specific
expenditures would otherwise require prior approval, the grantee must obtain
NIH approval before incurring the cost. NIH prior approval is required for any
costs to be incurred more than 90 days before the beginning date of the initial
budget period of a new or renewal award.
The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred. NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project. See NIH Grants Policy Statement https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm.
6. Other Submission Requirements
PD/PI Credential (e.g., Agency Login)
The NIH requires the PD(s)/PI(s) to fill in his/her Commons User ID in the "PROFILE – Project Director/Principal Investigator" section, "Credential" log-in field of the "Research & Related Senior/Key Person Profile" component.
Organizational DUNS
The applicant organization must include its DUNS number in its Organization Profile in the eRA Commons. This DUNS number must match the DUNS number provided at CCR registration with Grants.gov. For additional information, see "Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications."
PHS398 Research Plan Component Sections
The Research Strategy section of the R01 application may not exceed 12 pages, including tables, graphs, figures, diagrams, and charts. See Table of Page Limits
All application instructions outlined in the SF424 (R&R) Application Guide are to be followed, incorporating "Just-in-Time" information concepts
Specific Instructions for
Applications Requesting $500,000 (direct costs) or More per Year
Applicants requesting $500,000 or more in direct costs for any year (excluding consortium F&A costs) must carry out the following steps:
1) Contact the IC program staff at least 6 weeks before submitting the application, i.e., as plans are being developed for the study;
2) Obtain agreement
from the IC staff that the IC will accept the application for consideration for
award; and,
3) Include a cover letter with the application that identifies the staff member and IC who agreed to accept assignment of the application.
This policy applies to all new, renewal, revision, or resubmission applications. See NOT-OD-02-004, October 16, 2001.
Appendix Materials
Applicants must follow the specific instructions on Appendix materials as described in the SF424 (R&R) Application Guide (See https://grants.nih.gov/grants/funding/424/index.htm).
Do not use the Appendix to circumvent the page limitations. An application that does not comply with the required page limitations may be delayed in the review process.Resource Sharing Plan(s)
NIH considers the sharing of unique research resources developed through NIH-sponsored research an important means to enhance the value and further the advancement of the research. When resources have been developed with NIH funds and the associated research findings published or provided to NIH, it is important that they be made readily available for research purposes to qualified individuals within the scientific community. If the final data/resources are not amenable to sharing, this must be explained in the Resource Sharing section of the application (see https://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm.)
(a) Data Sharing Plan: Investigators seeking $500,000 or more in direct costs in any year are expected to include a brief 1-paragraph description of how final research data will be shared, or explain why data-sharing is not possible. Applicants are encouraged to discuss data-sharing plans with their NIH program contact (see Data-Sharing Policy or https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html.)
(b) Sharing Model Organisms: Regardless of the amount requested, all applications in which the development of model organisms is anticipated are expected to include a description of a specific plan for sharing and distributing unique model organisms and related resources, or state appropriate reasons why such sharing is restricted or not possible (see Sharing Model Organisms Policy, and NIH Guide NOT-OD-04-042.)
(c) Genome-Wide Association Studies (GWAS): Regardless of the amount requested, applicants seeking funding for a genome-wide association study are expected to provide a plan for submission of GWAS data to the NIH-designated GWAS data repository, or provide an appropriate explanation why submission to the repository is not possible. A genome-wide association study is defined as any study of genetic variation across the entire genome that is designed to identify genetic associations with observable traits (e.g., blood pressure or weight) or the presence or absence of a disease or condition. For further information see Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (NOT-OD-07-088) and https://grants.nih.gov/grants/gwas/.
Foreign Applications (Non-domestic [non-U.S.] Entities)
Indicate how the proposed project has specific relevance to the mission and objectives of the NIH/IC and has the potential for significantly advancing the health sciences in the United States.
Section V. Application Review Information
1. Criteria
Only the review criteria described below will be considered in the review process.
2. Review and
Selection Process
Review Process
Applications submitted for this funding opportunity will be assigned on the basis of established PHS referral guidelines to the ICs for funding consideration.
Applications that are complete will be evaluated for scientific and technical merit by an appropriate peer review group in accordance with NIH peer review procedures (http://grants1.nih.gov/grants/peer/), using the review criteria stated below.
As part of the scientific peer review, all applications will:
The mission of the NIH is to support science in pursuit of knowledge about the biology and behavior of living systems and to apply that knowledge to extend healthy life and reduce the burdens of illness and disability. As part of this mission, applications submitted to the NIH for grants or cooperative agreements to support biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Overall Impact. Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following five core review criteria, and additional review criteria (as applicable for the project proposed).
Core Review Criteria. Reviewers will consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance. Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the research integrate and utilize advances in imaging, sensing, and delivery to advance the field of drug and gene delivery? Will the overall project provide knowledge of therapeutic efficacy, the in vivo biochemical interactions involved in the therapeutic pathway, and also guide the design of next generation carriers to enhance therapy? Is the proposed therapeutic formulation appropriate for the disease under study? Is the proposed collaborative project likely to result in new engineering principles for delivery systems with imaging capabilities for translational research?
Investigator(s). Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Is there both drug/gene and imaging expertise on the team? Is there evidence that the team can work together effectively?
Innovation. Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach. Are the overall
strategy, methodology, and analyses well-reasoned and appropriate to accomplish
the specific aims of the project? Are potential problems, alternative
strategies, and benchmarks for success presented? If the project is
in the early stages of development, will the strategy establish feasibility and
will particularly risky aspects be managed?
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed? Will the developed system(s) enable correlations between properties and intracellular function? Will the project assess in vivo characteristics? Does the plan include both drug/gene delivery AND imaging? Does the proposed research overcome barriers to targeted delivery and utilize current advances in cellular or molecular imaging? Will the proposed work provide an understanding of target distribution, pharmacokinetics, and biomarkers needed to design appropriate delivery systems? Does the proposed project include imaging techniques coupled with biomarkers and/or sensors for the quantitative assessment of the location, magnitude, and time variation of drugs released, genes expressed, or other therapeutic measures? Are appropriate performance outcomes used to assess targeting strategies? Does the project utilize the unique skills and capabilities of both disciplines in a complementary way? Will there be a prototype at the end of the budget period?
Environment. Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Does the project propose an infrastructure with translational in vivo imaging capabilities that supports the in vivo assessment of technologies?
Additional Review Criteria
As applicable for the project proposed, reviewers will consider the following additional items in the determination of scientific and technical merit, but will not give separate scores for these items.
Protections for Human Subjects. For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials.
Inclusion of Women, Minorities, and Children. When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children.
Vertebrate Animals. The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia.
Resubmission Applications. When reviewing a Resubmission application (formerly called an amended application), the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewal Applications. When reviewing a Renewal application (formerly called a competing continuation application), the committee will consider the progress made in the last funding period.
Revision Applications. When reviewing a Revision application (formerly called a competing supplement application), the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
Biohazards. Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Additional Review Considerations
As applicable for the project proposed, reviewers will address each of the following items, but will not give scores for these items and should not consider them in providing an overall impact/priority score.
Budget and Period Support. Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Select Agents Research. Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Applications from Foreign Organizations. Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Resource Sharing Plans. Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm); 2) Sharing Model Organisms (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-04-042.html); and 3) Genome Wide Association Studies (GWAS) (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-088.html).
Selection Process
Applications submitted in response to this funding opportunity will compete for available funds with all other recommended applications. The following will be considered in making funding decisions:
3. Anticipated Announcement and Award Dates
Not Applicable
Section VI. Award Administration Information
Award Notices
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the NIH eRA Commons.
the application is under consideration for funding, NIH will request
"just-in-time" information from the applicant. For details,
applicants may refer to the NIH
Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards,
Subpart A: General.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official.
Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See Section IV.5., "Funding Restrictions."
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities.
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated.
We encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research (program), peer review, and financial or grants management issues:
1. Scientific/Research Contact(s):
Steven Zullo, Ph.D.
Gene and Drug Delivery, Nanotechnology Program Director
NIBIB, Division of Discovery Science and Technology
Democracy II-227
GIBB (Govt Issued Blackberry): 240-271-7097
Fax: 301-480-1614
Danthi, Ph.D.
Advanced Technologies and Surgery Branch
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health
6701 Rockledge Drive Rm 8218
Bethesda 20892
Telephone: (301) 435-0513
Email: firstname.lastname@example.com
2. Peer Review Contact(s):
Not Applicable
3. Financial/Grants Management Contact(s):
Angelos Bacas
Grants Management Specialist
National Institute of Biomedical Imaging and Bioengineering
6707 Democracy Boulevard, Suite 900
Bethesda, MD 20892-5477
Telephone: (301) 451-4782
Email: firstname.lastname@example.com
Section VIII. Other Information
Required Federal Citations
Use of Animals
in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (https://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (https://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects
Federal regulations (45 CFR 46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety
Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (Phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants ("NIH Policy for Data and Safety Monitoring," NIH Guide for Grants and Contracts, https://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (https://grants.nih.gov/grants/policy/data_sharing). Investigators should seek guidance from their institutions, on issues related to institutional policies and local institutional review board (IRB) rules, as well as local, State and Federal laws and regulations, including the Privacy Rule.
Policy for Genome-Wide
Association Studies (GWAS):
NIH is interested in advancing genome-wide association studies (GWAS) to identify common genetic factors that influence health and disease through a centralized GWAS data repository. For the purposes of this policy, a genome-wide association study is defined as any study of genetic variation across the entire human genome that is designed to identify genetic associations with observable traits (such as blood pressure or weight), or the presence or absence of a disease or condition. All applications, regardless of the amount requested, proposing a genome-wide association study are expected to provide a plan for submission of GWAS data to the NIH-designated GWAS data repository, or provide an appropriate explanation why submission to the repository is not possible. Data repository management (submission and access) is governed by the Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies, NIH Guide NOT-OD-07-088. For additional information, see https://grants.nih.gov/grants/gwas/.
Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see https://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh-Dole Act (see the NIH Grants Policy Statement. Beginning October 1, 2004, all investigators submitting an NIH application or contract proposal are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.
Access to Research Data through the Freedom of
Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are: (1) first produced in a project that is supported in whole or in part with Federal funds; and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this funding opportunity in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.
Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research" (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the SF424 (R&R) application; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.
All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (https://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human Subject
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for Federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-116.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov/). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research.
NIH Public Access Policy Requirement:
In accordance with the NIH Public Access Policy, investigators funded by the NIH must submit or have submitted for them to the National Library of Medicine's PubMed Central (see http://www.pubmedcentral.nih.gov/), an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication. The NIH Public Access Policy is available at (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-033.html). For more information, see the Public Access webpage at http://publicaccess.nih.gov/.
Standards for Privacy of Individually Identifiable
Health Information:
The Department of Health and Human Services (HHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule", on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the HHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. For publications listed in the appendix and/or Progress report, Internet addresses (URLs) or PubMed Central (PMC) submission identification numbers must be used for publicly accessible on-line journal articles. Publicly accessible on-line journal articles or PMC articles/manuscripts accepted for publication that are directly relevant to the project may be included only as URLs or PMC submission identification numbers accompanying the full reference in either the Bibliography & References Cited section, the Progress Report Publication List section, or the Biographical Sketch section of the NIH grant application. A URL or PMC submission identification number citation may be repeated in each of these sections as appropriate. There is no limit to the number of URLs or PMC submission identification numbers that can be cited.
Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This FOA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50% of their time (at least 20 hours per week based on a 40 hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov/.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
Research (OER)
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
Username or email *
Password *
Remember Me
Log in
Email address *
A password will be sent to your email address.
Subscribe to our newsletter
Your personal data will be used to support your experience throughout this website, to manage access to your account, and for other purposes described in our privacy policy.
No products in the cart.
Ⓒ TD Mercado (UK) Limited & Dwarkadhish E-Commerce Private Limited. Created by Gnosys Digital | Hosted on TD Web Services


text:
FAA furloughs continue to cause flight delays
WASHINGTON (CNNMoney) -- On Wednesday morning, federal furloughs hit travelers headed to Chicago.
Airlines flying into Chicago's O'Hare International Airport faced delays of at least 30 minutes, after fewer air traffic controllers reported for duty on Wednesday morning.
The Department of Transportation said Wednesday staff furloughs are also causing delays to flights headed to Las Vegas and Tampa.
"Controllers will space planes farther apart so they can manage traffic with current staff, which will lead to delays at airports including Chicago O'Hare, Las Vegas and Tampa," the agency said in a statement.
Controllers are being forced to take unpaid time off by the Federal Aviation Administration, which has to cut $600 million of its spending by September. It's part of the forced spending cuts at federal agencies that went into effect on March 1 to save the government $85 billion.
With fewer staff members at the Chicago Terminal Radar Approach Tower in Elgin, Illinois, flights into O'Hare were most affected on Wednesday. That office controls all air traffic in the Chicagoland area, said union officials.
As more controllers report to duty this afternoon, the delays are expected to ease.
"In the next three to four hours staffing should improve for the evening shift and we can land on a third runway," said Dan Carrico, a controller for O'Hare airport. By noon, some of the delays had been trimmed to about 15 minutes.
As a result of employee furloughs due to sequestration, the FAA is implementing traffic management initiatives at airports and facilities around the country. Travelers can expect to see a wide range of delays that will change throughout the day depending on staffing and weather related issues. For example, the FAA is experiencing staffing challenges at the Miami and Los Angeles En Route Centers, the Tampa TRACON, and Chicago O'Hare and Tampa Towers. Controllers will space planes farther apart so they can manage traffic with current staff, which will lead to delays at airports including Chicago O'Hare, Las Vegas and Tampa. The FAA also expects delays at a number of other airports because of weather and winds.
The FAA will continue to work with the airlines throughout the day to try and minimize delays for travelers. We encourage all travelers to check their flight status and also to visit fly.faa.gov for the latest airport delay information.
Yesterday more than 1,025 delays in the system were attributable to staffing reductions resulting from the furlough. There were more than 975 additional delays as a result of weather and other factors.
Airport delays started on Sunday, when furloughs kicked in for 47,000 Federal Aviation Administration workers, including 15,000 air traffic controllers. Each day, as many as 1,500 controllers or 10% of the workforce are being forced to take time unpaid off to save money.
The delays have mostly been centered around large airports in the New York area, Los Angeles and Dallas. There were 1,200 delays on Monday specifically tied to fewer air traffic controllers at work, according to the transportation agency. Weather and other factors caused another 1,400 delays. On Sunday, the agency reported 400 delays due to furloughs.
The log jam is expected to continue as each FAA employee has to take 11 furlough days through September.
Transportation Secretary Ray LaHood has said he had no choice but to resort to furloughs at the FAA to save money. In a call with reporters on Tuesday, he dismissed accusations that FAA furloughs are politically motivated to make budget cuts feel worse than they are.
In the meantime, the FAA is considering temporarily shelving a rule that currently stops airlines from keeping passengers sitting in planes on tarmacs longer than three or four hours, to keep air traffic flowing.
The airline lobbying group Airlines for America is pushing for the option of keeping passengers on planes longer to help accommodate delays from furloughs.
Airlines want to "minimize and avoid worsening the disruption and inconvenience to our passengers," said Katie Connell, managing director for the group.
Lawmakers on Capitol Hill on Wednesday grilled FAA director Michael Huerta, asking him why he didn't warn about flight delays and why the agency didn't detail delays for airlines until last week.
"We told them to expect significant delays at major hubs," Huerta said.
"Well. Lah-tee-dah. Everyone knew that. That's what sequester is all about," said Hal Rogers, a Republican from Kentucky, who runs the House Appropriations panel.


text:
The Carrie Diaries premiered to weak ratings on the CW Monday night, possibly entering itself into the canon of CW shows destined to be forgotten. But don't fret too hard, Carrie — that's actually part of a noble tradition, passed down from the UPN and WB. Indeed, lots of great shows toiled in obscurity on those networks, some for many years! And we're not talking about your Buffy or Gilmore Girls or Felicity — those shows both enjoyed enormous critical attention during their runs and continue to rightly occupy prime portions of pop real estate. But there are other shows that seem never to come up, that don't get endlessly dissected or lovingly detailed on Wikipedia, shows that deserved more recognition back in the day and deserve it still now. This list only includes shows that aired on the WB or UPN, not shows that were CW-only. Ah, nostalgia.
1. Nowhere Man, 1995, UPN
Bruce Greenwood starred as a photojournalist whose identity disappears all around him: Suddenly no one recognizes him, and every piece of evidence that he's ever existed is gone. If Nowhere had aired in the Lost era of TV mystery shows, we'd still be wading through tweets theorizing about it. As it is, it's not on Netflix or Amazon, and even the DVDs are out of print.
2. Grosse Pointe, 2001, WB
Darren Star's satirical teen soap about the cast of an earnest teen soap lasted just one season, but it's aged incredibly well and deserves a renewed round of consideration — especially given our insatiable appetite for behind-the-scenes gossip for teen shows in particular. (Glee. We're talking about Glee.) Put this show on Netflix Instant already.
3. Popular, 1999, WB
Speaking of teen soaps, Popular! Ryan Murphy might have three shows on TV at this very moment, but Murhpy's Ur-text will always be Popular.
4. Girlfriends, 2000, UPN
One of the many casualties of the 2007–08 writers strike, Girlfriends never got the finale it deserved (even though its spinoff, The Game, is still on BET). The show is just plain funny, but it flew under most critics' radars for its entire run.
5. Everwood, 2002, WB
Emily VanCamp is the star of Revenge. Chris Pratt is a fan favorite on Parks and Recreation. Sarah Drew makes April bearable on Grey's Anatomy. But no one talks about how they were all on one of the greatest family dramas ever, Everwood! It has all the weeping of Parenthood and the earnestness of an ABC Family show, with a little bit of small-town folksiness thrown in.
6. Roswell, 1999, WB
Like Buffy, Roswell moved from the WB to UPN after low ratings doomed it in its initial home. Unlike Buffy, it seems like no one cares about Roswell, even though the shows both used supernatural elements as a metaphor for the alienation of adolescence. Roswell isn't as witty as Buffy (is anything?), but it was created by Friday Night Lights' Jason Katims, so it's full of feelings.
7. Jake 2.0, 2004, UPN
There was a time when the nerdosphere could not stop talking about Chuck, the show about a geek who gets special powers thanks to some government computer thingie. But what about Jake 2.0, a show about a geek who gets special powers thanks to some government computer thingie? Jake was sharp and funny and exactly the kind of show you expect to be canceled almost immediately, which it was.
8. The Jamie Foxx Show, 1996, WB
The show ran for five seasons and was rerun on BET for years, but most current profiles of Jamie Foxx barely acknowledge that he had his own sitcom for 100 episodes. Guess what? He was great in it.
9. Young Americans, 2000, WB
A Dawson's Creek spinoff with Ian Somerhalder, Charlie Hunnam, and Katherine Moenning should have been superhot. Boarding school! Gender bending! Unbelievably obnoxious product placement! We still can't believe this show didn't catch on.


text:
Will you see a greater influx of patients at your practice? Or will more practices be forced to shut their doors to this patient population?
When the Supreme Court on Thursday morning upheld the 2010 healthcare law in a 5 to 4 decision, the fact that the insurance mandate would remain intact dominated the first round of news cycles. But perhaps more important to the practice-based physician is the high court's treatment of the Medicaid provision.
The Medicaid expansion portion of the Affordable Care Act calls for coverage of individuals up to 133 percent of the poverty level, or an additional 17 million Americans, starting in 2014. In return, the federal government would pick up all healthcare costs for the first few years, and 90 percent of expenses after that.
In an effort to ensure that physicians don't shut their doors to Medicaid patients for lackluster reimbursement, the health law will increase Medicaid pay to primary-care doctors to Medicare levels in 2013 and 2014, which will increase reimbursement by an average of about 34 percent, according to the American Academy of Family Physicians.
Originally, the law mandated that states that did not adopt the Medicaid expansion would no longer be eligible to receive any Medicaid funding at all. But with the high Court's decision to let states decide whether to accept additional funding to expand their existent Medicaid programs, the future of healthcare coverage for the lowest-income citizens is no longer clear cut.
Already, governors in a number of conservative-leaning states - including Kansas, Nebraska, and South Carolina - have said they would have trouble affording any additional costs even if the federal government picks up the bulk of the tab. Others have vowed never to participate in the program. Democratic congressional leaders, meanwhile, have issued press releases espousing the merits of expanded Medicaid coverage.
In an interview with MSNBC, former CMS Administrator Donald Berwick seemed pretty confident that all states, eventually, would accept benefits and terms of the Medicaid expansion the same way all states came around to enrolling in the original Medicaid program unveiled as part of the Social Security Act of 1965.
Still, so many questions remain as to how this will play out for physician practices over the next several years. Will practices whose physicians already treat Medicaid patients see their profits fall because reimbursements for these patients are lower than for patients with Medicare or third-party insurers? Or will the influx of new patients give fledgling practices a financial boost?
Many practice docs say the Medicaid expansion is bad news all around.
Witchita, Kan.-based internist George Watson opted out of Medicaid more than 10 years ago, and Medicare nine years ago, because reimbursement was affecting his ability to provide high-quality care.
"If you look at what the payments are for Medicaid right now, that's why most doctors don't participate," Watson told Physicians Practice. "I'm really concerned for my peers who provide Medicaid services. It will force more doctors to drop Medicaid. So the government will say 'you're covered," but the patients can't find a doctor who will see them."
Ken Bradley, vice president of strategic planning for Navicure, an Internet-based medical claims clearinghouse, said practices in every state should brace themselves for a potential for increase in patients by making sure their existing technology is robust enough to handle the volume.
"It's a fair assumption that one or more states will go along with the ACA [Medicaid provision], and Medicaid eligibility is going to increase dramatically," Bradley told Physicians Practice. "We're telling our practices to make sure they have all their ducks in a row. We're making sure processing is working as well as it can, that payer response, remittance, and eligibility information is automated. We're identifying specific Medicaid plans where there is potential for improvement in the electronic claims revenue cycle process."
But Miranda Franco, a government affairs representative for Medical Group Management Association, said it may be too early to tell how the provision will pan out.
"There is a concern that there could be a fall in physician supply," Franco told Physicians Practice. "We'll have this whole new population to cover, but will there be access [to care]? We're seeing a lot of physicians saying they won't accept more Medicare patients in this environment. You might see the same with providers, saying the same thing with Medicaid patients."


text:
Michael Parekowhai's Venice Biennale exhibition On First Looking into Chapman's Homer opened at Te Papa on Friday. The installation looks stunning, clustered in the middle of the space and the sound with the acoustics of the gallery with that high ceiling is wonderful.
The exhibition is only on for a month till September 23 2012, so a short exhibition period. I hope many people come in to experience this installation while it is here.
It is the first time the three major elements of Michael's installation have been shown in one gallery space – the two black bronze replica piano's and bulls and He Korero Purakau mo Te Awanui o Te Motu; story of a New Zealand river, 2011, the elaborately carved red 'Maori piano' – the playable steinway concert grand.
It is also perhaps the last time for a little while that this installation will be seen together.


text:
The collection of the State Hermitage includes more than three million works of art and artefacts of the world culture.
Among them are paintings, graphic works, sculptures and works of applied art, archaeological finds and numismatic material.
The main architectural ensemble of the Hermitage situated in the centre of St Petersburg consists of the Winter Palace, the former state residence of the Russian emperors, the buildings of the Small, Old (Great) and New Hermitages, the Hermitage Theatre and the Auxiliary House. The museum complex also includes the Menshikov Palace and the Eastern Wing of the General Staff building, the Staraya Derevnya Restoration and Storage Centre and the Museum of the Imperial Porcelain Factory.
The Winter Palace through the Ages
This movie devoted to the Winter Palace, the residence of the Russian emperors, enables you to make a unique journey through time.
Computer models present the palace and its surroundings in different historical eras - in the reigns of Nicholas I (mid-19th century) and Nicholas II (late 19th - early 20th century), and in the present day. The panoramas are accompanied by commentaries and supplemented by paintings and graphic art as well as photographs.


text:
I got my MiFi less than 24 months ago, and I wrote about it six months later, with this bit about the costs:
I liked the idea of a prepaid account because I just wanted to buy the device and the "pay as you go" model fit my usage. Of course you can't predict the future, and those Virgin Mobile folks have changed the pricing more than once. When I was planning to buy one, the 3 options were $10, $20, and $40, and by the time I bought one weeks later, it was $20, $40, and $50. And who know? They may change again…. Urgh.
Just dropping this in as a point of reference… the current prices are $35 for 2GB per month, and $55 for 5GB per month, and there's an "unlimited" for $50 per month which gives you "3G speeds up to 2.5GB" which I assume means any data over 2.5GB will be delivered at the speed of a 14.4 modem. I'm not sure if the $50 is available to me because I'm grandfathered in, or not, but this is the kind of shit that drives me crazy. I mean, I knew the price would increase, just like I'm sure the price of Adobe's Creative Cloud subscription will increase, which is why no matter how "cheap" it is right now, I can't be convinced it'll be some amazing deal in the long run…
I'm not sure that Virgin Mobile is still the best solution for my MiFi needs (which end up being maybe 3 to 5 times per year) but I don't know what the other (cheaper?) options might be… I did find TruConnect, which might be an option, but I'm open to suggestions.


text:
The Paper Mill Playhouse production of Lionel Bart's family-friendly musical Oliver! officially opened Dec. 1 at 7 PM at the New Jersey venue following previews that began Nov. 21.
Helmed by artistic director Mark S. Hoebee with original choreography by JoAnn M. Hunter, the production continues through Dec. 29.
The cast features David Garrison (Fagin), Betsy Morgan (Nancy), John Treacy Egan (Mr. Bumble), Jose Llana (Bill Sikes), David Hess (Mr. Brownlow), Ethan Haberfield (Artful Dodger) and Tyler Moran as Oliver with Kristen Smith Davis (Bet), Michael Di Liberto (Mr. Sowerberry), Dierdre Friel (Mrs. Sowerberry), Juliane Godfrey (Charlotte), Barbara Marineau (Mrs. Bedwin), Jeremy Morse (Noah) and Jessica Sheridan. Rounding out the ensemble are Adrian Arrieta, Kate Bailey, Casey Beidel, Monica Bradley, Stephen Mitchell Brown, Casey Erin Clark, Will Flamm, Kyle Garvin, Matthew Hooper, Devin Johnson, Mary Claire King, Hunter Kovacs, Jimmy Larkin, George Merrick, Sarah M. O'Connor, Patrick O'Neill, PJ Palmer, Jason Pintar, Jeff Sullivan, Bronwyn Tarboton, Joseph Torello and Joseph C. Townsend.
The locally-cast Workhouse Boys include Bobby Axelrod (Montclair, NJ), Luke Berninger (Wayne, NJ), Jake Cedar (Haddonfield, NJ), James Freedson-Jackson (South Orange, NJ), Chance Friedman (Basking Ridge, NJ), Lucas Imhoff (Madison, NJ), Jeffrey Kishinevskiy (Tenafly, NJ), Colton Maurer (Mahwah, NJ), Tyler Pelton (East Brunswick, NJ), Jake Walsh (Wall, NJ), Arthur Wawrzyniak (Morristown, NJ) and twin brothers Lee Rosenthal and Ryan Rosenthal (Cranford, NJ).
Adapted from the novel by Charles Dickens, the musical, according to press notes, tells the "miraculous tale of a young orphan's quest to find home and family in Victorian London." Song titles include "Food, Glorious Food," "Who Will Buy?," "As Long As He Needs Me" and "Consider Yourself."
The creative team also includes music director Craig Barna, costume designer Amanda Seymour, lighting designer F. Mitchell Dana, sound designer Randy Hansen, hair and wig designer Leah J. Loukas, set coordinator Timothy R. Mackabee, fight choreographer, dialect coach Shane Ann Younts, scenic designer Mark Morton and production stage manager Andrea Cibelli.
Tickets may be purchased by calling (973) 376-4343, at the Paper Mill Playhouse Box Office at 22 Brookside Drive in Millburn.


text:
Pope Francis called women "fundamental" to the Catholic Church today, angering Catholics who believe women should stay away from holy matters because Jesus preferred bros to hos. Is the pope a feminist?!? Let's break it down.
What He Said
From Reuters:
Francis, elected last month as the first non-European pope in 1,300 years, said women had always had a special mission in the Church as "first witnesses" of Christ's resurrection, and because they pass belief onto their children and grandchildren.
"In the Church, and in the journey of faith, women have had and still have a special role in opening doors to the Lord," Francis told thousands of pilgrims at his weekly audience in S. Peter's Square.
He said that in the Bible, women were not recorded as witnesses to Christ's resurrection because of the Jewish Law of the time that did not deem women or children to be reliable witnesses.
"In the Gospels, however, women have a primary, fundamental role ... The evangelists simply narrate what happened: the women were the first witnesses. This tells us that God does not choose according to human criteria," Francis said.
What Conservatives Think
The Vatican's official stance on ladies is that women can't be priests because Jesus Christ chose only men as his apostles. Conservatives employed the same argument last week, when Pope Francis dared to wash two women's feet on Holy Thursday, angering Catholics who consider the custom a re-enactment of Jesus washing the feet of his apostles, who were all dudes. We could spend a significant amount of time listing things Vatican officials do that Jesus did not do — use running water, not get crucified, etc. — but, somehow, I don't think that will stop them from bringing up the "What Would Jesus Do? NOT hang with women" argument.
What Reform Catholics Think
Catholics who think women should be able to join the priesthood say Jesus was simply conforming to the customs of his times by choosing an all-male posse. They're also not totally floored by Francis' opinions on women.
The head of the Women's Ordination Conference, which calls for women to be treated equally in the Church and to be allowed to become priests and bishops, said Francis's words were the most encouraging she had heard in her lifetime, but did not go far enough.
"While the pope was trying to be positive about women's role, where he's actually wrong is that women were actually disciples, like Mary Magdalene," WOC Executive Director Erin Saiz Hanna told Reuters.
"He said women are able to communicate Christ's words, but actually women can't preach so that's a false statement."
But judging on this past week alone — one lady foot-washing and one lady compliment — we're curious and maybe even a tad optimistic about the future. "Sources inside the Vatican have said Francis could reform the Vatican's bureaucracy and restructure or even close down the Vatican's bank after a series of scandals at the heart of the Holy See that damaged the Church's reputation," Reuters reports. What's next?


text:
Travel Nurse RN - ICU - Intensive Care Unit - $1,210-1,334 per week
Company: American Mobile Healthcare
Location: Bowling Green
Posted on: September 17, 2023
Job Description:
American Mobile Healthcare is seeking a travel nurse RN ICU -
Intensive Care Unit for a travel nursing job in BOWLING GREEN,
Kentucky.Job Description & Requirements
Registered Nurse - Intensive Care - ICU - Travel - (ICU RN)
StartDate: 10/2/2023
Available Shifts: 12 N
Pay Rate: $1210.00 - $1334.00
This position presents an opportunity to join an elite team of passionate physicians and nurses within the Intensive Care Unit (ICU).
- 211-bed hospital serving Southern Kentucky and surrounding areas. Recognized by the Joint Commission as a Top Performer, the facility is also an Accredited Chest Pain Center and a Certified Primary Stroke Center.
You'll find a challenging and rewarding environment where patient care is firmly rooted in compassion, innovation, and a drive for great outcomes.
Required QualificationsYears of Experience: 2. 1. Perm KY or compact RN License (#/expiration)2. ACLS, BLS
Job Benefits
At AMN Healthcare we take care of our travelers! We offer:
Competitive pay rates
Free, quality, private housing
Medical, Dental, Vision
401(k) and Flex Spending
Life Insurance
Accident and Short-term Disability Coverage
Free Continuing Education
Refer a friend and earn extra cash!
About the Company
Since its inception in 1985, American Mobile Healthcare has set the highest standards in professional recruitment for the travel healthcare industry. Our professional staffing team offers unparalleled customer service and industry commitment, as well as top pay and benefits. American Mobile Healthcare is an EEO/AA/Disability/Protected Veteran Employer.-- We encourage minority and female applicants to apply
Critical care nurse, CCU RN, intensive care nurse, ICU nurse, ICU nursing, ICU, intensive care, critical care, registered nurse, RN, R.N., nurse, nursing, healthcare, health care, patient care
American Mobile Healthcare Job ID #2865635. Pay package is based on 12 hour shifts and 36 hours per week (subject to confirmation) with tax-free stipend amount to be determined. Posted job title: Registered Nurse - Intensive Care - ICU - Travel - (ICU RN)About American Mobile HealthcareAmerican Mobile
Get paid to travel! American Mobile Healthcare is a leader in the travel nurse staffing industry with top travel nursing jobs in all 50 states, including some exclusive jobs that are only available for to nurses that work with American Mobile. As an American Mobile travel nurse, you'll be able to explore the country while earning great pay. We are proud to offer our travelers competitive benefits including:
Get started on your adventure with an American Mobile job. We'll take you to new places and your career to new heights.Benefits
American Mobile Healthcare is seeking a travel nurse RN ICU - Intensive Care Unit for a travel nursing job in BOWLING GREEN, Kentucky.Job Description & Requirements
Keywords: American Mobile Healthcare, Bowling Green , Travel Nurse RN - ICU - Intensive Care Unit - $1,210-1,334 per week, Healthcare , Bowling Green, Kentucky
here to apply!